79 related articles for article (PubMed ID: 17035731)
1. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques.
Langermans JA; Hensmann M; van Gijlswiik M; Zhang D; Pan W; Giersing BK; Locke E; Dubovsk F; Wittes J; Thomas AW
Hum Vaccin; 2006; 2(5):222-6. PubMed ID: 17035731
[TBL] [Abstract][Full Text] [Related]
2. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.
Kusi KA; Remarque EJ; Riasat V; Walraven V; Thomas AW; Faber BW; Kocken CH
Malar J; 2011 Jul; 10():182. PubMed ID: 21726452
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
Pierce MA; Ellis RD; Martin LB; Malkin E; Tierney E; Miura K; Fay MP; Marjason J; Elliott SL; Mullen GED; Rausch K; Zhu D; Long CA; Miller LH
Vaccine; 2010 Mar; 28(10):2236-2242. PubMed ID: 20051276
[TBL] [Abstract][Full Text] [Related]
6. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
Malkin E; Hu J; Li Z; Chen Z; Bi X; Reed Z; Dubovsky F; Liu J; Wang Q; Pan X; Chen T; Giersing B; Xu Y; Kang X; Gu J; Shen Q; Tucker K; Tierney E; Pan W; Long C; Cao Z
Vaccine; 2008 Dec; 26(52):6864-73. PubMed ID: 18930094
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
Roestenberg M; Remarque E; de Jonge E; Hermsen R; Blythman H; Leroy O; Imoukhuede E; Jepsen S; Ofori-Anyinam O; Faber B; Kocken CH; Arnold M; Walraven V; Teelen K; Roeffen W; de Mast Q; Ballou WR; Cohen J; Dubois MC; Ascarateil S; van der Ven A; Thomas A; Sauerwein R
PLoS One; 2008; 3(12):e3960. PubMed ID: 19093004
[TBL] [Abstract][Full Text] [Related]
10. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.
Arévalo-Herrera M; Vera O; Castellanos A; Céspedes N; Soto L; Corradin G; Herrera S
Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):21-7. PubMed ID: 21292874
[TBL] [Abstract][Full Text] [Related]
11. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.
Saul A; Lawrence G; Allworth A; Elliott S; Anderson K; Rzepczyk C; Martin LB; Taylor D; Eisen DP; Irving DO; Pye D; Crewther PE; Hodder AN; Murphy VJ; Anders RF
Vaccine; 2005 Apr; 23(23):3076-83. PubMed ID: 15811655
[TBL] [Abstract][Full Text] [Related]
12. Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.
Moreno A; Caro-Aguilar I; Yazdani SS; Shakri AR; Lapp S; Strobert E; McClure H; Chitnis CE; Galinski MR
Vaccine; 2008 Aug; 26(34):4338-44. PubMed ID: 18573299
[TBL] [Abstract][Full Text] [Related]
13. Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.
Zhu D; McClellan H; Dai W; Gebregeorgis E; Kidwell MA; Aebig J; Rausch KM; Martin LB; Ellis RD; Miller L; Wu Y
Vaccine; 2011 May; 29(20):3640-5. PubMed ID: 21440641
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.
McCarthy JS; Marjason J; Elliott S; Fahey P; Bang G; Malkin E; Tierney E; Aked-Hurditch H; Adda C; Cross N; Richards JS; Fowkes FJ; Boyle MJ; Long C; Druilhe P; Beeson JG; Anders RF
PLoS One; 2011; 6(9):e24413. PubMed ID: 21949716
[TBL] [Abstract][Full Text] [Related]
15. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.
Saul A; Hensmann M; Sattabongkot J; Collins WE; Barnwell JW; Langermans JA; Wu Y; Long CA; Dubovsky F; Thomas AW
Parasite Immunol; 2007 Oct; 29(10):525-33. PubMed ID: 17883455
[TBL] [Abstract][Full Text] [Related]
17. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
Herrera S; Fernández OL; Vera O; Cárdenas W; Ramírez O; Palacios R; Chen-Mok M; Corradin G; Arévalo-Herrera M
Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):12-20. PubMed ID: 21292873
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.
Hu J; Chen Z; Gu J; Wan M; Shen Q; Kieny MP; He J; Li Z; Zhang Q; Reed ZH; Zhu Y; Li W; Cao Y; Qu L; Cao Z; Wang Q; Liu H; Pan X; Huang X; Zhang D; Xue X; Pan W
PLoS One; 2008 Apr; 3(4):e1952. PubMed ID: 18398475
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
[TBL] [Abstract][Full Text] [Related]
20. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
